Profound Medical Corp. (PROF) - Q3 2025 Filing Summary
Business Context and Reporting Period
Profound Medical Corp. is a commercial-stage medical device company developing incision-free therapeutic systems for tissue ablation, primarily the TULSA-PRO system for prostate treatment and Sonalleve for uterine fibroids and bone metastases. This Form 10-Q covers the quarterly period ended September 30, 2025. The Company is a Foreign Private Issuer that voluntarily elected to file this report.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Revenue | $5.29M | $2.83M | $10.12M | $6.50M |
| Gross Profit | $3.93M | $1.79M | $7.40M | $4.08M |
| Gross Margin | 74% | 63% | 73% | 63% |
| Net Loss | ($7.98M) | ($9.37M) | ($34.40M) | ($22.87M) |
| Operating Cash Flow | N/A | N/A | ($31.64M) | ($17.57M) |
| Cash & Equivalents | $24.83M | $27.12M | $24.83M | $27.12M |
| Long-Term Debt | $4.48M (Current) | $4.66M | $4.48M (Current) | $4.66M |
Note: Debt is classified as current due to a projected covenant breach.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 87% quarter-over-quarter (Q3 2025 vs. Q3 2024) and 56% year-to-date, driven by higher capital equipment sales and recurring revenue in the United States.
- Margin Expansion: Gross margin improved to 74% in Q3 2025 from 63% in the prior year quarter, attributed to manufacturing efficiency improvements and a higher mix of capital equipment sales.
- Expense Increases: Operating expenses rose 19% in Q3 and 43% YTD. R&D expenses increased due to the CAPTAIN clinical trial and headcount growth. SG&A expenses rose due to sales force expansion and marketing events.
- Cash Position: Cash balances decreased from $54.9M at year-end 2024 to $24.8M at September 30, 2025, reflecting a net cash burn of $31.6M in operating activities over the nine-month period.
Outlook, Risks, and Contingencies
- Going Concern Uncertainty: Management has disclosed a material uncertainty regarding the Company's ability to continue as a going concern. Current cash balances are deemed insufficient to fund operations for the next 12 months, necessitating additional financing.
- Debt Covenant Breach: The Company projects a violation of its CIBC Credit Agreement liquidity covenant by June 30, 2026. Consequently, the entire $4.48M debt obligation has been reclassified as a current liability. While currently in compliance, failure to secure a waiver or refinance could result in the debt becoming immediately due.
- Internal Control Weakness: A material weakness in internal controls over financial reporting related to revenue recognition (ASC 606) identified in 2024 remains under remediation. Management is expanding the finance team and engaging consultants to address this.
- Financing Needs: The Company intends to seek additional equity or debt financing. Failure to secure funding could force curtailment of operations, clinical trials, or product development.
Investor Verification Checklist
- Verify the status of the Company's efforts to secure additional financing to address the going concern warning.
- Monitor the Company's ability to negotiate a waiver or amendment for the projected CIBC debt covenant breach expected in mid-2026.
- Review the progress of the remediation plan for the material weakness in internal controls over revenue recognition.
- Assess the sustainability of the 74% gross margin as capital equipment sales fluctuate.
- Track the enrollment and results of the CAPTAIN clinical trial, which is a primary driver of R&D expense increases.